[ACAD] ACADIA Pharmaceuticals Inc.


Type of security: Stock

Sector: Health Care

Industry: Major Pharmaceuticals

Market Capitalization:

Exchange: NASDAQ

The data is delayed by 15 minutes.


Price: 29.75 Change: 2.08 (7.52%)
Ext. hours: 29.65 Change: -0.1 (-0.34%)

chart ACAD

Refresh chart

Strongest Trends Summary For ACAD

ACAD is in the long-term up 880% in 16 years.

Horizon: 3 hours | 2 days | 5 days | 10 days | 1 month | 6 months | 1 year | 2 years | 5 years | max

Chart type: absolute | relative to S&P

Publish chart


Description: ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in neurological and related central nervous system disorders. The company has a pipeline of product candidates led by Pimavanserin that is in the Phase III development as a first-in-class treatment for Parkinson?s disease psychosis, and in Phase II development for Alzheimer?s disease psychosis; and has completed Phase II trial as a co-therapy for schizophrenia. It also has clinical-stage programs for chronic pain and glaucoma in collaboration with Allergan, Inc. and two advanced preclinical programs directed at Parkinson?s disease and other neurological disorders. ACADIA Pharmaceuticals Inc. was founded in 1993 and is headquartered in San Diego, California.

Fundamental Ratios
Shares Outstanding EPS-2.61 EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y Sales Growth - 4 Quarters -85.71% Sales Growth - Q/Q-91.67% P/E-10.38
P/E To EPS Growth P/S P/BV Price/Cash Per Share
Price/Free Cash Flow ROA-38.09% ROE-40.35% ROI
Current Ratio18.01 Quick Ratio Long Term Debt/Equity Debt Ratio0.06
Gross Margin Operating Margin-123217% Net Profit Margin-122364% Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities1.44 M Cash From Investing Activities38.47 M Cash From Operating Activities-25.35 M Gross Profit
Net Profit-40.38 M Operating Profit-40.55 M Total Assets301.96 M Total Current Assets299.9 M
Total Current Liabilities16.65 M Total Debt Total Liabilities16.87 M Total Revenue
Technical Data
High 52 week39.14 Low 52 week15.12 Last close17.87 Last change1.53%
RSI52.92 Average true range0.66 Beta1.75 Volume3.38 M
Simple moving average 20 days0.08% Simple moving average 50 days-2.47% Simple moving average 200 days-35.73%
Performance Data
Performance Week2.47% Performance Month-2.14% Performance Quart-30.98% Performance Half-40.61%
Performance Year-34.78% Performance Year-to-date-40.65% Volatility daily1.95% Volatility weekly4.36%
Volatility monthly8.94% Volatility yearly30.98% Relative Volume1230.89% Average Volume2.95 M
New High New Low


2020-06-02 09:00:00 | ACADIA Pharmaceuticals to Present at the Goldman Sachs 41st Annual Global Healthcare Conference on June 9, 2020

2020-06-02 07:27:00 | Is Acadia Pharmaceuticals a Buy?

2020-05-28 09:00:00 | ACADIA Pharmaceuticals Appoints Mark Schneyer as Senior Vice President, Business Development and Chief Business Officer

2020-05-27 12:15:04 | ACADIA to Merge Two Phase III Studies on Nuplazid for MDD

2020-05-26 09:00:00 | ACADIA Pharmaceuticals to Combine CLARITY-2 and CLARITY-3 Phase 3 Studies Evaluating Pimavanserin for the Adjunctive Treatment of Major Depressive Disorder

2020-05-21 09:00:00 | ACADIA Pharmaceuticals to Present Pimavanserin Clinical Data at the 2020 American Society of Clinical Psychopharmacology Virtual Annual Meeting

2020-05-09 08:02:05 | Analysts Have Made A Financial Statement On ACADIA Pharmaceuticals Inc.'s NASDAQ:ACAD First-Quarter Report

2020-05-08 22:31:17 | Acadia Pharmaceuticals ACAD Q1 2020 Earnings Call Transcript

2020-05-08 16:27:35 | Edited Transcript of ACAD earnings conference call or presentation 7-May-20 8:30pm GMT

2020-05-08 10:55:02 | ACADIA's ACAD Q1 Earnings & Revenues Fall Shy of Estimates

2020-05-07 18:10:10 | Acadia Pharmaceuticals ACAD Reports Q1 Loss, Lags Revenue Estimates

2020-05-07 16:06:00 | ACADIA Pharmaceuticals Reports First Quarter 2020 Financial Results

2020-05-07 16:05:00 | ACADIA Pharmaceuticals and Vanderbilt University Announce Exclusive License Agreement and Research Collaboration

2020-05-05 16:05:00 | ACADIA Pharmaceuticals to Present at Two Upcoming Virtual Investor Conferences

2020-04-30 12:34:04 | Acadia Pharmaceuticals ACAD Expected to Beat Earnings Estimates: Should You Buy?

2020-04-15 16:05:00 | ACADIA Pharmaceuticals to Announce First Quarter 2020 Financial Results on May 7, 2020

2020-04-13 09:43:23 | We're Not Worried About ACADIA Pharmaceuticals's NASDAQ:ACAD Cash Burn

2020-03-27 11:31:03 | Why Is Acadia ACAD Up 1.1% Since Last Earnings Report?

2020-03-22 22:04:50 | Largest Insider Trades of the Week

2020-03-20 14:11:31 | Hedge Funds Have Never Been This Bullish On ACADIA Pharmaceuticals Inc. ACAD

2020-03-04 07:37:10 | The Daily Biotech Pulse: Takeda Jumps Into The COVID-19 Fray, Exact Sciences Buys Cancer Diagnostics Companies

2020-03-03 17:50:00 | ACADIA Pharmaceuticals and Neuren Pharmaceuticals Announce Rare Pediatric Disease Designation for Trofinetide for the Treatment of Rett Syndrome

2020-02-28 20:35:00 | Don’t Expect Virgin Galactic Shares to Keep Rocketing Upward

2020-02-28 13:54:25 | ACADIA Pharmaceuticals Inc. Just Released Its Yearly Results And Analysts Are Updating Their Estimates

2020-02-27 11:13:04 | ACADIA ACAD Q4 Earnings Surpass, Nuplazid Drives Sales

2020-02-27 03:10:19 | Edited Transcript of ACAD earnings conference call or presentation 26-Feb-20 10:00pm GMT

2020-02-26 17:35:10 | Acadia Pharmaceuticals ACAD Reports Q4 Loss, Tops Revenue Estimates

2020-02-26 16:05:00 | ACADIA Pharmaceuticals Reports Fourth Quarter and Full Year 2019 Financial Results

2020-02-24 09:00:00 | ACADIA Pharmaceuticals to Present at the Cowen and Company 40th Annual Health Care Conference on March 2, 2020

2020-02-19 12:31:05 | Acadia Pharmaceuticals ACAD May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

2020-02-12 09:00:00 | ACADIA Pharmaceuticals to Announce Fourth Quarter and Full Year 2019 Financial Results on February 26, 2020

2020-02-05 06:13:12 | Analysts Expect Breakeven For ACADIA Pharmaceuticals Inc. NASDAQ:ACAD

2020-01-29 05:00:00 | ACADIA- From Depression to Schizophrenia

2020-01-17 08:45:01 | ACADIA ACAD Up More Than 100% in the Past Year: Here's Why

2020-01-10 11:54:24 | How Did ACADIA Pharmaceuticals Inc. ACAD Perform In Comparison to Hedge Fund Favorites in 2019?

2020-01-07 09:00:00 | ACADIA Pharmaceuticals to Present at the 38th Annual J.P. Morgan Healthcare Conference on January 14, 2020

2020-01-05 17:36:00 | Best Stocks of the Decade: Acadia's Drug Development Success

2019-12-23 11:30:04 | Has ACADIA Pharmaceuticals ACAD Outpaced Other Medical Stocks This Year?

2019-12-22 07:12:16 | Can You Imagine How Chuffed ACADIA Pharmaceuticals's NASDAQ:ACAD Shareholders Feel About Its 215% Share Price Gain?

2019-12-19 10:18:03 | Biotech Stock Outlook: M&A Activity Retains Growth Streak

2019-12-18 16:05:00 | ACADIA Pharmaceuticals Appoints Stephanie Fagan as Senior Vice President, Corporate Affairs and Chief Communications Officer

2019-12-17 08:38:01 | 5 Biotech Stocks That Have More Than Doubled This Year

2019-12-12 11:56:15 | The Zacks Analyst Blog Highlights: ACADIA, Compugen, Cue Biopharma, Epizyme and Krystal Biotech

2019-12-11 09:04:02 | 5 Biotech Stocks Up More Than 100% This Year So Far

2019-12-06 07:39:38 | The Daily Biotech Pulse: Cassava Gains On Alzheimer's Presentation, Bristol-Myers Hikes Dividend

2019-12-06 05:00:00 | A 60% Tumble for Sage Therapeutics, and Two More Numbers to Know

2019-12-05 23:01:02 | Hedge Funds Snapped Up ACADIA Pharmaceuticals Inc. ACAD Before The Q4 Rally

2019-12-05 16:08:46 | Why This Highflying Biotech Stock Zoomed Near A Profit-Taking Zone

2019-12-05 10:08:00 | Biotech Stocks Are Making Wild Moves Amid a Deluge of Trial Data

2019-12-05 07:14:16 | The Daily Biotech Pulse: Aurinia Rips Higher On Positive Readout, Sesen Bio On Track For Vicinium BLA Submission